Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
GlobalData on MSN2d
J&J’s Spravato receives FDA label expansion for depression monotherapyThe FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
With thousands of press releases published each week, it can be difficult to keep up with everything on. To help healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback